Oclaiz (octreotide subcutaneous depot) / Camurus 
Welcome,         Profile    Billing    Logout  
 22 Diseases   3 Trials   3 Trials   20 News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Oclaiz (octreotide subcutaneous depot) / Camurus
NCT04076462 / 2019-001191-11: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

Completed
3
72
Europe, US, RoW
CAM2029 (octreotide subcutaneous depot), CAM2029, Matching placebo, placebo
Camurus AB
Acromegaly
05/23
05/23
NCT04125836 / 2019-002190-66: A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

Active, not recruiting
3
135
Europe, US, RoW
CAM2029 (octreotide subcutaneous depot), CAM2029
Camurus AB
Acromegaly
06/25
06/25
SORENTO, NCT05050942 / 2021-000849-40: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET

Active, not recruiting
3
332
Europe, Canada, US, RoW
CAM2029, Octreotide LAR, Lanreotide ATG
Camurus AB, Camurus AB
Gastro-enteropancreatic Neuroendocrine Tumor
12/25
12/27
2021-003764-27: This study is being conducted to evaluate efficacy and safety of Octreotide compared with Placebo via subcutaneous depot route in subjects with polycystic liver disease

Not yet recruiting
2/3
69
Europe
CAM2029 (Octreotide subcutaneous depot), CAM2029, Prolonged-release solution for injection
Camurus AB, Camurus AB
Polycystic liver disease, Multiple fluid filled sac in liver, Diseases [C] - Digestive System Diseases [C06]
 
 
POSITANO, NCT05281328 / 2021-003764-27: A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD

Active, not recruiting
2/3
71
Europe, US
CAM2029, octreotide subcutaneous depot, Placebo
Camurus AB, Camurus AB
Polycystic Liver Disease
02/25
08/27
2021-000598-95: A Phase 2, randomized, double-blind, placebo-controlled, multi-center trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 or other disorders Ensayo de fase II, aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia y la seguridad de octreotida subcutánea de liberación prolongada (CAM2029) en pacientes con síndrome de dificultad respiratoria aguda (SDRA) causado por COVID-19 u otros trastornos

Not yet recruiting
2
40
Europe
Octreotide subcutaneous depot, CAM2029, Prolonged-release solution for injection
Camurus AB, Camurus AB
Acute respiratory distress syndrome (ARDS) caused by COVID-19 or other disorders síndrome de dificultad respiratoria aguda (SDRA) causado por COVID-19 u otros trastornos, Acute respiratory distress syndrome síndrome de dificultad respiratoria aguda, Diseases [C] - Respiratory Tract Diseases [C08]
 
 

Download Options